Tandem Diabetes Care to acquire AMF Medical (Sigi Patch Pump) for up to CHF 200M

TANDEM DIABETES CARE INC

Cash payment of CHF 62.4M at closing plus CHF 8M prior strategic investment; earnouts up to CHF 129.6M.
Earnouts: CHF 38.4M upon key development milestones over next two years; CHF 91.2M upon FDA clearance of ACE pump.
Transaction expected to close January 2023, subject to no material adverse effect and other customary conditions.
Acquires Sigi Patch Pump technology, expanding insulin delivery pipeline for Tandem.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

TANDEM DIABETES CARE INC entered into Share Purchase Agreement with the Sellers listed on Annex B attached thereto and AMF Medical SA valued at CHF 62.4 million (effective 2022-12-10).

Action: entry
Agreement: asset purchase
Counterparty: the Sellers listed on Annex B attached thereto and AMF Medical SA
Value: CHF 62.4 million
Effective: 2022-12-10

Exact text from the filing

On December 10, 2022 , Tandem Diabetes Care, Inc., a Delaware corporation (the “Company”), entered into a Share Purchase Agreement (the “Purchase Agreement”) with the Sellers listed on Annex B attached thereto (collectively, the “Sellers” and each, individually, a “Seller”) and AMF Medical SA, a corporation organized and existing under the laws of Switzerland (“AMF Medical”).

View on SEC.gov

Browse all material agreements →

TANDEM DIABETES CARE INC filing history →

Source: SEC EDGAR

accession 0001438133-22-000257

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.